Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Hosted on MSN1mon
Lilly to Boost Obesity Drug Supply With $3 Billion Expansion(Bloomberg) -- Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its blockbuster diabetes and weight-loss drugs. The latest ...
The scholarship will pay for 4 years of tuition, fees and books at an Indiana public or private nonprofit college or ...
The U.K. will start offering Eli Lilly’s (LLY) weight loss drug Mounjaro next year, but will restrict the medicine to people with the greatest need as the country tries to adapt to new ways of ...
As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo Nordisk (NVO), its closest rival in the lucrative obesity drug market ...
The pharma giant continues to spend a lot of cash on important capital investments. Lilly's also spending a lot on clinical trials that could have big revenue implications. The stock trades at a ...
Lily Potter's role in the Harry Potter series was critical, but one of the most intriguing aspects of her character is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback